Global Neurology Clinical Trials Market by Study Design (Interventional, Expanded Access, Observational), by Phase (Phase III, Phase IV, Phase II, Phase I) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global neurology clinical trials market was valued at USD 4.8 million in 2020. It is projected to grow at a compound annual rate (CAGR of 5.5%) between 2021 and 2028. This can be attributed to the growing number of neurological diseases such as stroke, dementia, and peripheral neuropathy and increasing R&D investments in neurological research. Covid-19, however, is a unique event that has affected virtually every aspect of businesses around the globe. The pharma industry is also being tapped to assist in the development of a pandemic-fighting treatment. Data collection, trial enrolment and analysis were all affected, which caused delays in clinical trials. A total of 81 clinical trials for a specific neurological indication were affected by the pandemic as of April 15, 2020.
Many large pharma companies are focusing on neuroscience. AstraZeneca and Roche's experimental Alzheimer's treatments failed to pass late-stage testing. Biogen, a well-known neuroscience company, plans on convincing regulators to approve a drug similar to those that failed. After achieving success in Alzheimer's disease drug makers now turn their attention to spinal muscular atrophy. Effective therapies from Novartis and Biogen have been approved since 2016.
Drug makers have more tools than ever to correct and manipulate genes, in contrast to the 1990s or 2000s. Large corporations might be interested in a return to neuroscience if they can target disorders that are caused by single genetic mutations such as spinal muscular dystrophy. Pfizer, for example, has acquired Bamboo Therapeutics to help with Duchenne muscular dystrophy, and Roche expressed interest in Ion is Pharmaceuticals Huntington disease programs.
Technological innovations can also improve productivity and efficiency of neurology clinical trials by increasing patient engagement, reducing patient burden, and using novel outcomes. Virtual clinical trials, remote monitoring and wearable devices could help achieve the goal of making clinical trials more patient-focused.
Phase Insights
In 2020, the highest revenue share was held by phase II clinical trials. It dominated the market for neurology clinical trial and held 36.7% of the total market. Because neurological disorders are rare and not available for treatment, this is due in large part to the fact that they are very rare. The vast majority of trials are in phase II and III. Between 1999 and 2020, 8,205 CNS trials were performed. In 2020, 609 trials were completed.
Phase III is expected to experience the greatest growth over the forecast period. This may be due to the fact that the phase III clinical trials are most expensive and involve large numbers of participants. Phase III requires more patients and a longer treatment period. A phase III clinical trial for central nervous system is estimated to cost USD 19.2 billion. Between 1999 and 2020, 12,089 CNS trials have been conducted. In 2020, 629 CNS trials will be conducted.
Indication Insights
The fastest expected growth rate for Huntington's disease is 6.0% during the forecast period. This can be attributed to the increasing R&D investment as well as the high prevalence of Huntington's disease around the world. The EU Clinical Trials Register includes 40,633 trials that used the EudraCT protocol. 6629 of these included children under 18.
Egypt is the Arab world's most populous country. However, Huntington's disease research in Egypt is often neglected because it has a population of over 100 million. A new study shows that Huntington's disease is affecting 2.7 percent of the global population and 10 percent in Europe. The disease is found in 21 of every 100,000 Egyptians, or approximately 21,000 people. This rate is 11 times higher than that of the U.S. and doubles the Huntington's disease prevalence in Europe. Ireland (10.6 per 100,000), Norway (6.35), Australia (6.3), Denmark (5.7), Denmark (5.8) and the United Kingdom (5.4), Slovenia (5.5.2) and Sweden (4.7 are some of the countries with the highest Huntington's disease prevalence.
Study Design Insights
The market leader in neurology clinical trials was based on study design. In 2020, it accounted for the largest revenue share at 81.2%. This is the most common method for conducting clinical experiments. The majority of registered studies were related to drugs or biologics. Next came behavioral, clinical procedure and device intervention studies.
Over the forecast period, there will be significant growth in the observational market. In many situations, such post-marketing safety assessments of drugs or when clinical trial are not possible, observational studies can be used routinely to evaluate treatment effects. The prevalence of key prognostic indicators that are linked to treatment and outcome is often different between treatment groups in observational studies.
Regional Insights
North America was the dominant market for neurology clinical trials in 2020, accounting for 45.8% of the total revenue. Market for neurology clinical trial in the region is driven by the rising incidence of neurological disorders and the large number of participants in clinical trials. With an estimated 8.4million Americans over 65 suffering from Alzheimer's or other dementia by 2030, the market for neurology clinical trials in the region will grow as the population ages.
The market for neurology clinical trial services in the Middle East and Africa is expected to grow at 8.2% annually. Sub-Saharan Africa is home to many neurological, psychiatric and developmental disorders. This is despite the fact that there are more people suffering from stroke and other diseases that are linked with increasing longevity. Major depressive disorders, and post-traumatic stress disorder, are common problems in conflict-torn North Africa and the Middle East.
Market Share Insights & Key Companies
Market players are taking a variety of strategic steps to strengthen their services and gain a competitive edge, including new partnerships, collaborations, mergers, acquisitions and geographic expansions.
Sosei, which is based in Japan and Pharm Enable (based in the U.K.) partnered in January 2021 to develop drugs for a G protein coupled receptor (GPCR), target that has been linked to several neurological disorders. To study neurological diseases treatment, they used advanced chemistry and artificial intelligence-enabled tech. The following are some of the most prominent players in the market for neurology clinical trials:
-
Novartis
-
Covance
-
Medpace
-
Charles River Laboratories
-
Syneous Health
-
Icon Plc
-
GlaxoSmithKline
-
Aurora healthcare
-
Biogen
-
IQVIA
Up Market Research published a new report titled “Neurology Clinical Trials Market research report which is segmented by Study Design (Interventional, Expanded Access, Observational), by Phase (Phase III, Phase IV, Phase II, Phase I), By Players/Companies Syneous Health, Charles River Laboratories, Covance, Medpace, Icon Plc, Aurora healthcare, Novartis, IQVIA, Biogen, GlaxoSmithKline”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Neurology Clinical Trials Market Research Report |
| By Study Design | Interventional, Expanded Access, Observational |
| By Phase | Phase III, Phase IV, Phase II, Phase I |
| By Companies | Syneous Health, Charles River Laboratories, Covance, Medpace, Icon Plc, Aurora healthcare, Novartis, IQVIA, Biogen, GlaxoSmithKline |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 244 |
| Number of Tables & Figures | 171 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Neurology Clinical Trials Market Report Segments:
The market is segmented by Study Design (Interventional, Expanded Access, Observational), by Phase (Phase III, Phase IV, Phase II, Phase I).
Neurology Clinical Trials Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Neurology Clinical Trials Market
Overview of the regional outlook of the Neurology Clinical Trials Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Neurology Clinical Trials Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Neurology Clinical Trials Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Interventional
2. Expanded Access
3. Observational
7. By Phase:1. Phase III
2. Phase IV
3. Phase II
4. Phase I
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neurology Clinical Trials Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Neurology Clinical Trials Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neurology Clinical Trials Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neurology Clinical Trials Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neurology Clinical Trials Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neurology Clinical Trials Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neurology Clinical Trials Market Size & Forecast, 2018-2028
4.5.1 Neurology Clinical Trials Market Size and Y-o-Y Growth
4.5.2 Neurology Clinical Trials Market Absolute $ Opportunity
Chapter 5 Global Neurology Clinical Trials Market Analysis and Forecast by Study Design
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Study Design
5.1.2 Basis Point Share (BPS) Analysis by Study Design
5.1.3 Absolute $ Opportunity Assessment by Study Design
5.2 Neurology Clinical Trials Market Size Forecast by Study Design
5.2.1 Interventional
5.2.2 Expanded Access
5.2.3 Observational
5.3 Market Attractiveness Analysis by Study Design
Chapter 6 Global Neurology Clinical Trials Market Analysis and Forecast by Phase
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Phase
6.1.2 Basis Point Share (BPS) Analysis by Phase
6.1.3 Absolute $ Opportunity Assessment by Phase
6.2 Neurology Clinical Trials Market Size Forecast by Phase
6.2.1 Phase III
6.2.2 Phase IV
6.2.3 Phase II
6.2.4 Phase I
6.3 Market Attractiveness Analysis by Phase
Chapter 7 Global Neurology Clinical Trials Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neurology Clinical Trials Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Neurology Clinical Trials Analysis and Forecast
9.1 Introduction
9.2 North America Neurology Clinical Trials Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neurology Clinical Trials Market Size Forecast by Study Design
9.6.1 Interventional
9.6.2 Expanded Access
9.6.3 Observational
9.7 Basis Point Share (BPS) Analysis by Study Design
9.8 Absolute $ Opportunity Assessment by Study Design
9.9 Market Attractiveness Analysis by Study Design
9.10 North America Neurology Clinical Trials Market Size Forecast by Phase
9.10.1 Phase III
9.10.2 Phase IV
9.10.3 Phase II
9.10.4 Phase I
9.11 Basis Point Share (BPS) Analysis by Phase
9.12 Absolute $ Opportunity Assessment by Phase
9.13 Market Attractiveness Analysis by Phase
Chapter 10 Europe Neurology Clinical Trials Analysis and Forecast
10.1 Introduction
10.2 Europe Neurology Clinical Trials Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neurology Clinical Trials Market Size Forecast by Study Design
10.6.1 Interventional
10.6.2 Expanded Access
10.6.3 Observational
10.7 Basis Point Share (BPS) Analysis by Study Design
10.8 Absolute $ Opportunity Assessment by Study Design
10.9 Market Attractiveness Analysis by Study Design
10.10 Europe Neurology Clinical Trials Market Size Forecast by Phase
10.10.1 Phase III
10.10.2 Phase IV
10.10.3 Phase II
10.10.4 Phase I
10.11 Basis Point Share (BPS) Analysis by Phase
10.12 Absolute $ Opportunity Assessment by Phase
10.13 Market Attractiveness Analysis by Phase
Chapter 11 Asia Pacific Neurology Clinical Trials Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neurology Clinical Trials Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neurology Clinical Trials Market Size Forecast by Study Design
11.6.1 Interventional
11.6.2 Expanded Access
11.6.3 Observational
11.7 Basis Point Share (BPS) Analysis by Study Design
11.8 Absolute $ Opportunity Assessment by Study Design
11.9 Market Attractiveness Analysis by Study Design
11.10 Asia Pacific Neurology Clinical Trials Market Size Forecast by Phase
11.10.1 Phase III
11.10.2 Phase IV
11.10.3 Phase II
11.10.4 Phase I
11.11 Basis Point Share (BPS) Analysis by Phase
11.12 Absolute $ Opportunity Assessment by Phase
11.13 Market Attractiveness Analysis by Phase
Chapter 12 Latin America Neurology Clinical Trials Analysis and Forecast
12.1 Introduction
12.2 Latin America Neurology Clinical Trials Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neurology Clinical Trials Market Size Forecast by Study Design
12.6.1 Interventional
12.6.2 Expanded Access
12.6.3 Observational
12.7 Basis Point Share (BPS) Analysis by Study Design
12.8 Absolute $ Opportunity Assessment by Study Design
12.9 Market Attractiveness Analysis by Study Design
12.10 Latin America Neurology Clinical Trials Market Size Forecast by Phase
12.10.1 Phase III
12.10.2 Phase IV
12.10.3 Phase II
12.10.4 Phase I
12.11 Basis Point Share (BPS) Analysis by Phase
12.12 Absolute $ Opportunity Assessment by Phase
12.13 Market Attractiveness Analysis by Phase
Chapter 13 Middle East & Africa (MEA) Neurology Clinical Trials Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neurology Clinical Trials Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neurology Clinical Trials Market Size Forecast by Study Design
13.6.1 Interventional
13.6.2 Expanded Access
13.6.3 Observational
13.7 Basis Point Share (BPS) Analysis by Study Design
13.8 Absolute $ Opportunity Assessment by Study Design
13.9 Market Attractiveness Analysis by Study Design
13.10 Middle East & Africa (MEA) Neurology Clinical Trials Market Size Forecast by Phase
13.10.1 Phase III
13.10.2 Phase IV
13.10.3 Phase II
13.10.4 Phase I
13.11 Basis Point Share (BPS) Analysis by Phase
13.12 Absolute $ Opportunity Assessment by Phase
13.13 Market Attractiveness Analysis by Phase
Chapter 14 Competition Landscape
14.1 Neurology Clinical Trials Market: Competitive Dashboard
14.2 Global Neurology Clinical Trials Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Syneous Health
14.3.2 Charles River Laboratories
14.3.3 Covance
14.3.4 Medpace
14.3.5 Icon Plc
14.3.6 Aurora healthcare
14.3.7 Novartis
14.3.8 IQVIA
14.3.9 Biogen
14.3.10 GlaxoSmithKline
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neurology Clinical Trials Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neurology Clinical Trials Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neurology Clinical Trials Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neurology Clinical Trials Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neurology Clinical Trials Market Size & Forecast, 2018-2028
4.5.1 Neurology Clinical Trials Market Size and Y-o-Y Growth
4.5.2 Neurology Clinical Trials Market Absolute $ Opportunity
Chapter 5 Global Neurology Clinical Trials Market Analysis and Forecast by Study Design
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Study Design
5.1.2 Basis Point Share (BPS) Analysis by Study Design
5.1.3 Absolute $ Opportunity Assessment by Study Design
5.2 Neurology Clinical Trials Market Size Forecast by Study Design
5.2.1 Interventional
5.2.2 Expanded Access
5.2.3 Observational
5.3 Market Attractiveness Analysis by Study Design
Chapter 6 Global Neurology Clinical Trials Market Analysis and Forecast by Phase
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Phase
6.1.2 Basis Point Share (BPS) Analysis by Phase
6.1.3 Absolute $ Opportunity Assessment by Phase
6.2 Neurology Clinical Trials Market Size Forecast by Phase
6.2.1 Phase III
6.2.2 Phase IV
6.2.3 Phase II
6.2.4 Phase I
6.3 Market Attractiveness Analysis by Phase
Chapter 7 Global Neurology Clinical Trials Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neurology Clinical Trials Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Neurology Clinical Trials Analysis and Forecast
9.1 Introduction
9.2 North America Neurology Clinical Trials Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neurology Clinical Trials Market Size Forecast by Study Design
9.6.1 Interventional
9.6.2 Expanded Access
9.6.3 Observational
9.7 Basis Point Share (BPS) Analysis by Study Design
9.8 Absolute $ Opportunity Assessment by Study Design
9.9 Market Attractiveness Analysis by Study Design
9.10 North America Neurology Clinical Trials Market Size Forecast by Phase
9.10.1 Phase III
9.10.2 Phase IV
9.10.3 Phase II
9.10.4 Phase I
9.11 Basis Point Share (BPS) Analysis by Phase
9.12 Absolute $ Opportunity Assessment by Phase
9.13 Market Attractiveness Analysis by Phase
Chapter 10 Europe Neurology Clinical Trials Analysis and Forecast
10.1 Introduction
10.2 Europe Neurology Clinical Trials Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neurology Clinical Trials Market Size Forecast by Study Design
10.6.1 Interventional
10.6.2 Expanded Access
10.6.3 Observational
10.7 Basis Point Share (BPS) Analysis by Study Design
10.8 Absolute $ Opportunity Assessment by Study Design
10.9 Market Attractiveness Analysis by Study Design
10.10 Europe Neurology Clinical Trials Market Size Forecast by Phase
10.10.1 Phase III
10.10.2 Phase IV
10.10.3 Phase II
10.10.4 Phase I
10.11 Basis Point Share (BPS) Analysis by Phase
10.12 Absolute $ Opportunity Assessment by Phase
10.13 Market Attractiveness Analysis by Phase
Chapter 11 Asia Pacific Neurology Clinical Trials Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neurology Clinical Trials Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neurology Clinical Trials Market Size Forecast by Study Design
11.6.1 Interventional
11.6.2 Expanded Access
11.6.3 Observational
11.7 Basis Point Share (BPS) Analysis by Study Design
11.8 Absolute $ Opportunity Assessment by Study Design
11.9 Market Attractiveness Analysis by Study Design
11.10 Asia Pacific Neurology Clinical Trials Market Size Forecast by Phase
11.10.1 Phase III
11.10.2 Phase IV
11.10.3 Phase II
11.10.4 Phase I
11.11 Basis Point Share (BPS) Analysis by Phase
11.12 Absolute $ Opportunity Assessment by Phase
11.13 Market Attractiveness Analysis by Phase
Chapter 12 Latin America Neurology Clinical Trials Analysis and Forecast
12.1 Introduction
12.2 Latin America Neurology Clinical Trials Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neurology Clinical Trials Market Size Forecast by Study Design
12.6.1 Interventional
12.6.2 Expanded Access
12.6.3 Observational
12.7 Basis Point Share (BPS) Analysis by Study Design
12.8 Absolute $ Opportunity Assessment by Study Design
12.9 Market Attractiveness Analysis by Study Design
12.10 Latin America Neurology Clinical Trials Market Size Forecast by Phase
12.10.1 Phase III
12.10.2 Phase IV
12.10.3 Phase II
12.10.4 Phase I
12.11 Basis Point Share (BPS) Analysis by Phase
12.12 Absolute $ Opportunity Assessment by Phase
12.13 Market Attractiveness Analysis by Phase
Chapter 13 Middle East & Africa (MEA) Neurology Clinical Trials Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neurology Clinical Trials Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neurology Clinical Trials Market Size Forecast by Study Design
13.6.1 Interventional
13.6.2 Expanded Access
13.6.3 Observational
13.7 Basis Point Share (BPS) Analysis by Study Design
13.8 Absolute $ Opportunity Assessment by Study Design
13.9 Market Attractiveness Analysis by Study Design
13.10 Middle East & Africa (MEA) Neurology Clinical Trials Market Size Forecast by Phase
13.10.1 Phase III
13.10.2 Phase IV
13.10.3 Phase II
13.10.4 Phase I
13.11 Basis Point Share (BPS) Analysis by Phase
13.12 Absolute $ Opportunity Assessment by Phase
13.13 Market Attractiveness Analysis by Phase
Chapter 14 Competition Landscape
14.1 Neurology Clinical Trials Market: Competitive Dashboard
14.2 Global Neurology Clinical Trials Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Syneous Health
14.3.2 Charles River Laboratories
14.3.3 Covance
14.3.4 Medpace
14.3.5 Icon Plc
14.3.6 Aurora healthcare
14.3.7 Novartis
14.3.8 IQVIA
14.3.9 Biogen
14.3.10 GlaxoSmithKline
Segments Covered in the Report
The global Neurology Clinical Trials market has been segmented based on
By Study Design
The global Neurology Clinical Trials market has been segmented based on
By Study Design
- Interventional
- Expanded Access
- Observational
- Phase III
- Phase IV
- Phase II
- Phase I
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- Syneous Health
- Charles River Laboratories
- Covance
- Medpace
- Icon Plc
- Aurora healthcare
- Novartis
- IQVIA
- Biogen
- GlaxoSmithKline
Our Clients
Related Reports
Some other reports from this category!
